



Unaudited Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2021 and 2020

Table of Contents

Unaudited condensed consolidated interim statements of financial position	1
Unaudited condensed consolidated interim statements of operations and comprehensive income	2
Unaudited condensed consolidated interim statements of changes in shareholders' equity	3
Unaudited condensed consolidated interim statements of cash flows	4
Notes to the unaudited condensed consolidated interim financial statements	5-13

Jamieson Wellness Inc.
Unaudited Condensed Consolidated Interim Statements of Financial Position
In thousands of Canadian dollars as at

	<u>Notes</u>	<u>September 30, 2021</u>	<u>December 31, 2020</u>
Assets			
Current assets			
Cash		9,150	1,166
Accounts receivable	3	105,636	97,951
Inventories	4	130,442	102,645
Derivatives	9	986	-
Prepaid expenses and other current assets		5,689	2,389
		251,903	204,151
Non-current assets			
Property, plant and equipment		94,320	83,796
Goodwill		122,975	122,975
Intangible assets		193,524	196,158
Deferred income tax		2,523	2,261
Total assets		665,245	609,341
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities		80,395	73,084
Income taxes payable		913	6,580
Derivatives	9	4,544	8,231
Current portion of other long-term liabilities		2,884	3,115
		88,736	91,010
Long-term liabilities			
Long-term debt	5	174,378	149,058
Post-retirement benefits		3,692	3,538
Deferred income tax		53,060	51,479
Other long-term liabilities		21,384	21,854
Total liabilities		341,250	316,939
Shareholders' equity			
Share capital	6	266,943	255,795
Contributed surplus		14,211	12,986
Retained earnings		44,874	29,023
Accumulated other comprehensive loss		(2,033)	(5,402)
Total shareholders' equity		323,995	292,402
Total liabilities and shareholders' equity		665,245	609,341

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Approved on behalf of the Board:

Steve Spooner
Director

David Williams
Director

Jamieson Wellness Inc.**Unaudited Condensed Consolidated Interim Statements of Operations and Comprehensive Income**

In thousands of Canadian dollars, except share and per share amounts

	Notes	Three months ended September 30,		Nine months ended September 30,	
		2021	2020	2021	2020
Revenue	10, 11	112,368	105,565	321,194	283,292
Cost of sales		71,555	67,520	208,169	181,050
Selling, general and administrative expenses		19,228	19,010	61,218	57,635
Share-based compensation	7	992	1,231	4,651	3,769
Earnings from operations		20,593	17,804	47,156	40,838
Foreign exchange gain		(577)	(271)	(444)	(172)
Other expenses		-	3	-	3
Interest expense and other financing costs	8	1,505	1,315	4,291	4,633
Earnings before income taxes		19,665	16,757	43,309	36,374
Provision for income taxes		5,381	4,613	11,417	10,181
Net earnings		14,284	12,144	31,892	26,193
Unrealized gain (loss) on amounts to be reclassified net of amounts reclassified to net earnings	9	3,748	(2,683)	4,673	(395)
Income tax		(993)	711	(1,238)	105
Total other comprehensive income (loss)		2,755	(1,972)	3,435	(290)
Comprehensive income		17,039	10,172	35,327	25,903
Earnings per share attributable to common shareholders:	12				
Basic, earnings per share		0.35	0.31	0.80	0.66
Diluted, earnings per share		0.34	0.29	0.77	0.63
Weighted average number of shares:	12				
Basic		40,256,983	39,741,698	40,076,485	39,430,417
Diluted		41,698,267	41,574,340	41,500,445	41,261,833

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Jamieson Wellness Inc.
Unaudited Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
In thousands of Canadian dollars

	Notes	Share capital	Contributed surplus	Retained earnings	Accumulated other comprehensive loss	Total shareholders' equity
As at December 31, 2020		255,795	12,986	29,023	(5,402)	292,402
Net earnings for the period		-	-	31,892	-	31,892
Issuance of treasury shares	6	11,148	(3,260)	-	-	7,888
Common share dividend (\$0.40 per share)		-	-	(16,041)	-	(16,041)
Other comprehensive income		-	-	-	3,435	3,435
Currency translation adjustment		-	-	-	(66)	(66)
Share-based compensation	7	-	4,485	-	-	4,485
As at September 30, 2021		266,943	14,211	44,874	(2,033)	323,995
		Share capital	Contributed surplus	Retained earnings	Accumulated other comprehensive (loss) income	Total shareholders' equity
As at December 31, 2019		243,224	10,727	6,061	(844)	259,168
Net earnings for the period		-	-	26,193	-	26,193
Issuance of treasury shares	6	11,974	(2,026)	-	-	9,948
Common share dividend (\$0.345 per share)		-	-	(13,654)	-	(13,654)
Other comprehensive income		-	-	-	(290)	(290)
Currency translation adjustment		-	-	-	33	33
Share-based compensation	7	-	3,429	-	-	3,429
As at September 30, 2020		255,198	12,130	18,600	(1,101)	284,827

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Jamieson Wellness Inc.
Unaudited Condensed Consolidated Interim Statements of Cash Flows
In thousands of Canadian dollars

Cash provided by (used in)	Notes	Three months ended September 30,		Nine months ended September 30,	
		2021	2020	2021	2020
Operating activities					
Net earnings		14,284	12,144	31,892	26,193
Items not affecting cash					
Depreciation of property, plant, and equipment and right-of-use assets		2,543	2,071	7,377	5,924
Amortization of intangible assets		1,081	1,059	3,194	2,951
Deferred income taxes		166	(444)	81	(241)
Share-based compensation	7	992	1,143	4,485	3,429
Others		93	153	192	336
Net change in non-cash working capital		(9,078)	(11,573)	(37,125)	(16,740)
		10,081	4,553	10,096	21,852
Investing activities					
Additions to property, plant and equipment, net		(6,596)	(1,471)	(16,325)	(7,166)
Acquisition of intangible assets		(19)	(328)	(560)	(1,783)
		(6,615)	(1,799)	(16,885)	(8,949)
Financing activities					
Proceeds from credit facilities	5	20,160	16,000	68,721	47,064
Repayment to credit facilities	5	(16,041)	(19,636)	(43,402)	(51,718)
Payment of lease liabilities		(830)	(555)	(2,393)	(1,597)
Exercise of stock options and ESPP	6	3,808	2,761	7,888	9,948
Dividends to Common Shareholders		(6,049)	(4,976)	(16,041)	(13,654)
		1,048	(6,406)	14,773	(9,957)
Increase (Decrease) in cash		4,514	(3,652)	7,984	2,946
Cash - Beginning of the period		4,636	6,796	1,166	198
Cash - End of the period		9,150	3,144	9,150	3,144
Supplemental disclosure					
Amount of income taxes paid		4,000	2,492	17,000	9,116
Amount of interest paid		1,412	986	3,473	3,335

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three and nine months ended September 30, 2021 and 2020

1. Company overview

1.1 Description of the business and consolidated financial statements

Jamieson Wellness Inc. (“Jamieson” or the “Company”) is a Canadian public company with common shares (“Common Shares”) listed on the Toronto Stock Exchange under the stock symbol “JWEL”.

The unaudited condensed consolidated interim financial statements of Jamieson and its subsidiaries for the three and nine months ended September 30, 2021 (the “Interim Financial Statements”) were authorized for issue by the Board of Directors of the Company on November 3, 2021. Jamieson is a company continued under the *Business Corporations Act* (Ontario) and resident in Canada. Jamieson’s registered office is located at 66 Wellington Street West, Suite 5300, TD Bank Tower, Toronto, ON, M5K 1E6.

The Company has manufacturing facilities located in Windsor, Ontario and in Toronto, Ontario and is principally engaged in the manufacturing, development, distribution, sales and marketing of branded and customer branded health products for humans including vitamins, herbal and mineral nutritional supplements.

1.2 Subsidiaries

The table below provides a summary of the Company’s subsidiaries. Unless otherwise stated, the subsidiaries as listed below have share capital consisting solely of common shares, which are held directly or indirectly by the Company.

As at Entity	September 30, 2021 %	December 31, 2020 %	Principal Place of Operations
Jamieson Laboratories Ltd.	100	100	Canada
International Nutrient Technologies Limited	100	100	Canada
Body Plus Nutritional Products Inc.	100	100	Canada
Jamieson Health Products (Shanghai) Co., Ltd.	100	100	China
Jamieson Health Products Australia Pty Ltd.	100	100	Australia
Jamieson Health Products UK Ltd.	100	100	United Kingdom
Jamieson Health Products USA Ltd.	100	100	United States of America
Jamieson Health Products Netherlands B.V.	100	-	Netherlands

2. Summary of significant accounting policies

Basis of preparation and statement of compliance

The Interim Financial Statements have been prepared in accordance with IAS 34, “Interim Financial Reporting”. They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2020 (the “Annual Financial Statements”). The Interim Financial Statements have been prepared using the same accounting policies as disclosed in the Annual Financial Statements. The Interim Financial Statements are presented in Canadian dollars and all values are rounded to the nearest thousand (\$000), except share and per share amounts and when otherwise indicated.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three and nine months ended September 30, 2021 and 2020

3. Accounts receivable

As at	September 30, 2021	December 31, 2020
	<u>\$</u>	<u>\$</u>
Trade	104,419	96,647
Other miscellaneous receivables	1,314	1,407
Allowance for expected credit losses	(97)	(103)
	<u>105,636</u>	<u>97,951</u>

The Company determines the allowance based on lifetime expected credit losses at each reporting date.

4. Inventories

As at	September 30, 2021	December 31, 2020
	<u>\$</u>	<u>\$</u>
Raw material and packaging	58,768	52,565
Bulk product and work in process	25,932	18,269
Packaged finished goods	48,437	34,605
Inventory provision	(2,695)	(2,794)
	<u>130,442</u>	<u>102,645</u>

An inventory provision is estimated by management based on historical sales, inventory aging and expiry, and expected future sales and is included in cost of sales. Subsequent changes to the provision are recorded in cost of sales in the unaudited condensed consolidated interim statements of operations and comprehensive income.

5. Long-term debt

On September 27, 2019, Jamieson Laboratories Ltd. (“JLL”) amended and restated its credit agreement to add Jamieson Health Products USA Ltd. (collectively with JLL the “Borrowers”) as a co-borrower and to provide a secured revolving facility of \$275,000 (including a \$10,000 swingline facility) with the option to increase the revolving facility by \$200,000 (collectively, the “Credit Facilities”). The Credit Facilities mature on September 27, 2024 with the outstanding principal repayable in full on this date.

The table below illustrates the drawings and repayments applied against the Credit Facilities.

	<u>Three months ended September 30,</u>		<u>Nine months ended September 30,</u>	
	2021	2020	2021	2020
	<u>\$</u>	<u>\$</u>	<u>\$</u>	<u>\$</u>
<u>Credit Facilities</u>				
Drawings	20,160	16,000	68,721	47,064
Repayments	(16,041)	(19,636)	(43,402)	(51,718)
	<u>4,119</u>	<u>(3,636)</u>	<u>25,319</u>	<u>(4,654)</u>

For the nine months ended September 30, 2021, the weighted average interest rate on the Credit Facilities was 2.7% (2020 – 3.2%).

The Credit Facilities are collateralized by security agreements and first charges over the assets including property, plant and equipment and intellectual property of the Borrowers and certain other subsidiaries of JLL, subject to permitted liens.

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three and nine months ended September 30, 2021 and 2020

Under the terms of the Credit Facilities, the Borrowers are subject to restrictive covenants and must maintain an interest coverage ratio of not less than 3.00:1.00 and a leverage ratio not greater than 4.00:1.00. The Borrowers are in compliance with all covenants as at the date of the Interim Financial Statements.

6. Share capital

	Common Shares	
	#	\$
As at December 31, 2020	39,872,912	255,795
Exercise of share-based awards	456,828	10,736
Employee stock purchase plan	12,467	412
As at September 30, 2021	40,342,207	266,943

	Common Shares	
	#	\$
As at December 31, 2019	38,989,942	243,224
Exercise of share-based awards	845,389	11,630
Employee stock purchase plan	12,869	344
As at September 30, 2020	39,848,200	255,198

As at September 30, 2021 and 2020, the authorized share capital consisted of:

- Unlimited number of Common Shares. The holders of Common Shares are entitled to receive dividends as declared from time to time, and are entitled to one vote per share at meetings of the Company.
- Unlimited number of Preference Shares, issuable in series.

7. Share-based compensation

Senior employees and directors' plan

The Company has an equity-based compensation plan providing for the issuance of securities under which grants will be made by the Company. Under the long-term incentive plan, the Board of Directors, at its discretion may grant share options, restricted shares, restricted share units in the form of time-based restricted share units ("RSUs") or performance-based share units ("PSUs"), deferred share units ("DSUs"), and stock appreciation rights. The awards are settled in Common Shares with a cash settlement alternative available to the Company.

A summary of the status of the Company's outstanding share-based awards and changes during the nine month period ended September 30, 2021 and year ended December 31, 2020 is presented below:

	September 30, 2021				December 31, 2020			
	Options (number of shares)	PSUs (number of shares)	RSUs (number of shares)	DSUs (number of shares)	Options (number of shares)	PSUs (number of shares)	RSUs (number of shares)	DSUs (number of shares)
Outstanding awards, beginning of period	2,546,553	256,894	9,000	-	2,919,776	187,903	18,000	-
Granted	456,319	39,909	-	16,907	515,862	68,991	-	-
Exercised	(361,122)	(95,706)	-	-	(858,301)	-	(9,000)	-
Forfeited	(18,710)	(3,061)	-	(1,463)	(30,784)	-	-	-
Outstanding awards, end of period	2,623,040	198,036	9,000	15,444	2,546,553	256,894	9,000	-
Awards exercisable, end of period	1,571,561	-	-	-	1,274,953	-	-	-

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three and nine months ended September 30, 2021 and 2020

The Company's share-based compensation expense for the three and nine months ended September 30, 2021 is \$992 and \$4,651, respectively (2020 - \$1,231 and \$3,769), of which \$992 and \$4,485 (2020 - \$1,143 and \$3,429) is classified as contributed surplus in the Company's consolidated financial statements and \$nil and \$166, respectively (2020 - \$88 and \$340) is related to employment taxes paid on exercise of options. In second quarter of the current year, the Company accelerated \$1,498 of share-based compensation expense in relation to the Company's CEO transition.

8. Interest expense and other financing costs

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
	\$	\$	\$	\$
Interest on debt and borrowings	1,270	1,143	3,596	4,186
Interest on lease liabilities	235	172	695	447
	1,505	1,315	4,291	4,633

9. Financial instruments and risk management activities

Financial instruments

Fair value measurement

All derivative instruments have been classified as Level 2 in the fair value hierarchy.

The fair values and notional amounts of derivative financial instruments shown below are as at:

	September 30, 2021				December 31, 2020			
	Notional Amount	Notional Amount	Fair Value		Notional Amount	Notional Amount	Fair Value	
			Asset	Liability			Asset	Liability
	\$CAD	\$USD	\$	\$	\$CAD	\$USD	\$	\$
Foreign currency forward contract designated as hedging instruments (forecast purchases)	-	75,000	-	(4,544)	-	117,000	-	(6,811)
Foreign currency forward contract designated as hedging instruments (forecast sales)	-	(63,000)	443	-	-	-	-	-
Interest rate swaps designated as hedging instruments	130,000	-	543	-	140,000	-	-	(1,420)
	130,000	12,000	986	(4,544)	140,000	117,000	-	(8,231)

On June 5, 2020, the Company entered into an interest rate swap with an effective date of October 1, 2020 to September 27, 2024 with a notional principal of \$140,000 and an annual amortization of \$10,000 on the first business day of each year. The notional principal of the interest rate swap is \$130,000 as at the end of this reporting period. The interest rate swap is a derivative measured at fair value and meets hedge accounting requirements.

The carrying values of financial assets and liabilities measured at amortized cost (excluding long-term debt) approximate their fair values due to their short-term nature.

The carrying value of long-term debt as at September 30, 2021 and December 31, 2020 approximates its fair value. The fair value of the Company's long-term debt was estimated based on discounted future cash flows using current rates for similar financial instruments subject to similar risks and maturities. The fair value of long-term debt is considered a Level 2 fair value measurement.

For the three and nine month period September 30, 2021 there were no transfers between levels.

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three and nine months ended September 30, 2021 and 2020

Financial instrument risk management objectives and policies

The Company is exposed to credit risk, market risk and liquidity risk. The Company's senior management oversees the management of these risks. The Company's financial instruments and policies for managing these risks are detailed below.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in financial loss to the Company. The Company is exposed to credit risk from its customers (primarily related to trade accounts receivable) in the normal course of business. The Company has adopted a policy of only dealing with creditworthy counterparties. To mitigate this risk, the Company carries out regular credit evaluations and purchases credit insurance for international customers, where appropriate, as a means of mitigating the risk of financial loss from defaults.

The Company is also exposed to counterparty credit risk inherent in its financing activities, trade receivable insurance, foreign currency derivatives and interest rate derivatives. The Company has assessed these risks as minimal.

Market risk

Foreign exchange risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily from transactions in U.S. dollars such as a portion of trade accounts payable, trade accounts receivable and cash.

The Company uses foreign exchange forward contracts to manage foreign exchange transaction exposure. As of September 30, 2021, \$99,567 (December 31, 2020 - \$156,124) of anticipated foreign currency denominated purchases have been hedged and \$80,253 (December 31, 2020 - \$nil) of anticipated foreign currency denominated sales have been hedged with underlying foreign exchange forward contracts settling at various dates in the 15 months proceeding the unaudited condensed consolidated interim statement of financial position date.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's accounts receivable and accounts payable are non-interest bearing. The Company's exposure to the risk of changes in market interest rates arises from long-term debt obligations issued at fixed rates that create fair value interest rate risk and variable rate borrowings that create cash flow interest rate risk.

The Company manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings. To further reduce the long-term interest rate exposure and gain predictability over future cash flows, the Company uses interest rate swaps, in which it agrees to exchange, at specified intervals, the difference between fixed and variable rate interest amounts calculated by reference to an agreed-upon notional principal amount.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three and nine months ended September 30, 2021 and 2020

With all other variables held constant, the sensitivity to a reasonably possible change in interest rates on floating rate borrowings of the Company would have the following impact to net earnings before taxes:

	Increase/ decrease in basis points	Effect on Earnings before tax
	+/-	\$
Three months ended September 30, 2021	100	134
Nine months ended September 30, 2021	100	342
Three months ended September 30, 2020	100	429
Nine months ended September 30, 2020	100	1,308

Changes in market interest rates cause the fair value of long-term debt with fixed interest rates to fluctuate but do not affect net earnings, as the Company's debt is carried at amortized cost and the carrying value does not change as interest rates change.

Commodity price risk

The Company is exposed to price risk related to purchases of certain commodities used as raw materials. The Company may use fixed price contracts with suppliers to mitigate commodity price risk. Concentration in any one raw material is not significant to the Company.

Liquidity risk

Liquidity risk is the risk the Company will not be able to meet its financial obligations associated with financial liabilities. The Company is exposed to this risk mainly in respect of its accounts payable and accrued liabilities, various long-term debt agreements, obligations under its post-retirement benefits plan and lease commitments. The Company manages its liquidity risk through continuous monitoring of its forecast and actual cash flows and through the management of its capital structure. The Company continually revises its available liquid resources as compared to the timing of the payment of liabilities to manage its liquidity risk.

As at September 30, 2021, the Company had \$109,772 in cash and available revolving and swingline facilities.

The contractual undiscounted principal cash flows payable in respect of financial liabilities as at the date of these Interim Financial Statements, were as follows:

As at	September 30, 2021	December 31, 2020
	\$	\$
Amounts payable in more than 12 months	207,797	178,377
Amounts payable in less than 12 months	84,195	77,089
	291,992	255,466

Impact of COVID-19

The COVID-19 pandemic continued to impact businesses globally throughout 2021. The progress on vaccinations in Canada has resulted in the gradual lifting of restrictions, permitting the reopening of retail channels, the easing of capacity limits in select settings and the incorporation of proof of vaccination where required. As the Canadian government and public health officials work towards a full reopening, there is a continuing risk that COVID-19 and variants of concern may impact the Company's results of operations or financial condition. Any prolonged retail or manufacturing closures could impact the Company's ability to

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three and nine months ended September 30, 2021 and 2020

service its customers and consumers. An outbreak within the Company's operating facilities could result in absenteeism or a plant closure for an extended duration. The Company's suppliers may experience a business disruption which could impact the supply of raw materials or components required for production. Limitations on transportation or border closures may result in shipment delays from the Company's suppliers or to its customers.

The Company continues to refine its safety protocols to ensure the health and wellness of its employees and business partners. In response to the province of Ontario's move to Step 3 of the *Reopening Ontario (A Flexible Response to COVID-19) Act, 2020*, the Company safely removed production shift gaps (scheduled downtimes between shifts implemented beginning the second quarter of 2020 to ensure no potential cross-contamination during shift changes), while continuing safety measures including the use of personal protective equipment, physical distancing and rapid antigen testing for all employees who are not fully vaccinated at its manufacturing facilities. For employees working from home since the pandemic began, the Company implemented a voluntary return to office option for fully vaccinated employees, amongst other safety measures. The Company continues to provide education and incentives to increase vaccination rates of its employees, along with shift premiums for its essential hourly staff who maintain production during government mandated measures. The Company continues to discourage non-essential travel for business and prioritizes work-from-home to conduct business where possible. As a result of the policies and procedures implemented, the Company's operations to date have been largely uninterrupted by the COVID-19 pandemic. The Company will continue to consider the removal of certain COVID-19 safety measures in accordance with Canadian government and public health recommendations.

As a result of COVID-19, consumers have continued to prioritize their health and wellness which has resulted in higher demand for both immunity and general health supplements. In response to the demand and continued global supply chain challenges, the Company ensured continuity of supply through securing additional and alternate sources of raw materials, expanding operating capacity, and carrying additional inventory.

The duration and impact of the COVID-19 pandemic remains unknown. This includes the rate and manner in which vaccines are distributed, as well as vaccine efficacy against future COVID-19 variants and strains. The Company will continue to review its safety protocols to reflect new government or public health recommendations. The Company has not benefited from nor applied for any government financial aid or relief fund relating to the COVID-19 pandemic.

Capital

The Company's objective is to maintain a cost-effective capital structure that supports its long-term growth strategy, supports the business and maximizes shareholder value. The Company typically uses leverage in its capital structure to reduce the cost of capital. The Company's goal is to maintain its primary credit ratios and leverage at levels that are designed to provide continued access to investment-grade credit pricing and terms.

The Company measures its credit profile using a number of metrics, some of which are non-IFRS measures, primarily cash, less long-term debt and bank indebtedness ("net cash (debt)") to earnings before interest, income taxes, depreciation, amortization, restructuring and other related costs, and interest coverage. Additionally, the Company maintains a cash flow reserve to service obligations as they come due.

In addition to credit facilities and equity, the Company uses leases as additional sources of financing.

There have been no material changes to the Company's risk management activities since the inception of the Company's operations.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three and nine months ended September 30, 2021 and 2020

10. Segment information

The Company has two reportable operating segments with all material operations carried out in Canada:

- The Jamieson Brands segment's principal activity is the manufacturing, distribution and marketing of branded natural health products including vitamins, minerals and supplements; and
- The Strategic Partners segment's principal activity is providing contract manufacturing services to consumer health companies and retailers worldwide.

The Company's chief operating decision maker evaluates segment performance on the basis of earnings from operations, as reported to internal management, on a periodic basis.

Inter-segment revenues and expenses are eliminated upon consolidation and relate mainly to sales from the Strategic Partners segment to the Jamieson Brands segment.

	For the three month period ended September 30, 2021		
	Jamieson Brands	Strategic Partners	Total
	\$	\$	\$
Revenue	<u>85,175</u>	<u>27,193</u>	<u>112,368</u>
Earnings from operations	<u>19,053</u>	<u>1,540</u>	<u>20,593</u>
Foreign exchange gain			(577)
Interest expense and other financing costs			1,505
Provision for income taxes			<u>5,381</u>
Net earnings			<u>14,284</u>

	For the three month period ended September 30, 2020		
	Jamieson Brands	Strategic Partners	Total
	\$	\$	\$
Revenue	<u>82,604</u>	<u>22,961</u>	<u>105,565</u>
Earnings from operations	<u>16,936</u>	<u>868</u>	<u>17,804</u>
Foreign exchange gain			(271)
Other expenses			3
Interest expense and other financing costs			1,315
Provision for income taxes			<u>4,613</u>
Net earnings			<u>12,144</u>

	For the nine month period ended September 30, 2021		
	Jamieson Brands	Strategic Partners	Total
	\$	\$	\$
Revenue	<u>243,461</u>	<u>77,733</u>	<u>321,194</u>
Earnings from operations	<u>42,412</u>	<u>4,744</u>	<u>47,156</u>
Foreign exchange gain			(444)
Interest expense and other financing costs			4,291
Provision for income taxes			<u>11,417</u>
Net earnings			<u>31,892</u>

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three and nine months ended September 30, 2021 and 2020

	For the nine month period ended September 30, 2020		
	Jamieson Brands	Strategic Partners	Total
	\$	\$	\$
Revenue	226,690	56,602	283,292
Earnings (loss) from operations	41,263	(425)	40,838
Foreign exchange gain			(172)
Other Expenses			3
Interest expense and other financing costs			4,633
Provision for income taxes			10,181
Net earnings			26,193

Share-based compensation is allocated to the Jamieson Brands operating segment.

11. Revenue from contracts with customers

The following table sets forth the disaggregation of the Company's revenue from contracts with customers in the Jamieson Brands operating segment:

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
	\$	\$	\$	\$
Domestic sales	71,151	68,203	201,117	189,383
International sales	14,024	14,401	42,344	37,307
Total revenue from contracts with customers	85,175	82,604	243,461	226,690

International sales are primarily denominated in U.S. dollars and subject to fluctuations in foreign exchange (see Note 9 – Financial instruments and risk management activities) on the conversion to Canadian dollars.

12. Earnings per share

Basic earnings per share amounts are calculated by dividing the net earnings attributable to common shareholders of the Company by the weighted average number of shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net earnings attributable to common shareholders of the Company by the weighted average number of shares outstanding during the period, adjusted for the effects of potentially dilutive share options, PSUs, RSUs and DSUs.

The following table sets forth the calculation of basic and diluted earnings per share:

	2021			2020		
	Net earnings available to common shareholders	Weighted average number of shares	EPS \$	Net earnings available to common shareholders	Weighted average number of shares	EPS \$
Three months ended September 30,						
<i>Basic</i>						
Continuing operations	14,284	40,256,983	0.35	12,144	39,741,698	0.31
<i>Diluted</i>						
Continuing operations	14,284	41,698,267	0.34	12,144	41,574,340	0.29
Nine months ended September 30,						
<i>Basic</i>						
Continuing operations	31,892	40,076,485	0.80	26,193	39,430,417	0.66
<i>Diluted</i>						
Continuing operations	31,892	41,500,445	0.77	26,193	41,261,833	0.63